Liver Cancer

 

RAD001 for Advanced Hepatocellular Carcinoma (UW09040)
A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study

Investigator: Samuel Whiting, MD, PhD;   Conditions: Hepatocellular Carcinoma (Liver Cancer);    Status: Recruiting;   Study ID: NCT01035229